Biotech Co.* (Symbol) | Pharma Co. (Country) | Product | Disclosed Funding (M) | Terms/Details (Date) |
|
Acambis plc (UK; ACAM; LSE:ACM) | Swiss Serum and Vaccine Institute Berne (Switzerland) | Oral typhoid vaccine | ND | Swiss Serum will fund all process development and supply of clinical trial materials and will manufacture the vaccine and supply it to Acambis; the companies will share the costs of the remaining trials of the vaccine; Acambis gains exclusive sales and marketing rights in the U.S. and Canada to sell an oral cholera vaccine, Orochol Berna, in combination with its oral typhoid vaccine (3/16) |
|
Applera Corp.(consists of two units: Applied Biosystems, NYSE:ABI; and Celera Genomics, NYSE:CRA) | Pantheco A/S (Denmark) | Peptide nucleic acids | ND | Applera's subsidiary Applied Biosystems Group acquired a small minority stake in Pantheco; agreement includes a nonexclusive license agreement to manufacture peptide nucleic acids for research and development purposes (3/7**) |
|
Biotech Holdings Ltd. (Canada; OTC BB:BIOHF) | Bilim Pharmaceuticals Inc. (Turkey) | DIAB II | ND | Bilim will distribute DIAB II in Turkey (3/27) |
|
Durect Corp. (DRRX) | Mallinckrodt Inc. | Sufentanil | ND | Durect recently completed patient enrollment for a Phase II trial of Duros sufentanil; Mallinckrodt will supply sufentanil to treat chronic pain (3/27) |
|
Lorus Therapeutics Inc. (Canada; LORFF; TSE:LOR) | Dalton Chemical Laboratories Inc. (Canada) | Virulizin | ND | The agreement will provide supply for the Phase III trial and prepare for potential commercial sales (3/12) |
|
MGI Pharma Inc. (MOGN) | Helsinn Healthcare SA (Switzerland) | Palonosetron | $11 | The deal includes $11M in up-front payments and grants MGI exclusive North American license and distribution rights (4/10) |
|
Pharsight Corp. (PHST) | iBiomatics LLC | Pharsight's Computer-Assisted Trial Design methodology | ND | iBiomatics will market the Pharsight Trial Simulator and iBiomatics' webbased platform for biomedical informatics (3/8) |
|
Vysis Inc. (VYSI) | Abbott Laboratories Inc. | Genomic tests related to breast and bladder cancer | ND | Abbott gets exclusive distribution rights in North America and Europe for the PathVysion HER-2 assay and the UroVysion assay (4/5) |
|
Xanthon Inc.* | CMED/RELA (division of Colorado MEDtech Inc.) | Xanthon Xpression Analysis Instrument | ND | Xanthon will begin receiving instruments in anticipation of a product launch in 2002; agreement is for the manufacturing for production quantities of the Xanthon Xpression Analysis Instrument (3/12) |
|
NOTES |
|||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
|||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
|||||
** Denotes the date the item ran in BioWorld International. |
|||||
ND = Not disclosed, reported and/or available |
|||||
|
LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
|||||
To read more on related topics, click on one of the words below.